Research programme: janus kinase inhibitors - Aclaris Therapeutics/ JAKPharm

Drug Profile

Research programme: janus kinase inhibitors - Aclaris Therapeutics/ JAKPharm

Alternative Names: JAK3 inhibitors - Aclaris Therapeutics/JAKPharm

Latest Information Update: 23 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JAKPharm
  • Developer Aclaris Therapeutics
  • Class
  • Mechanism of Action Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alopecia

Most Recent Events

  • 28 Mar 2016 Early research in Alopecia in USA (unspecified route)
  • 28 Mar 2016 Aclaris Therapeutics in-licenses JAK 3 inhibitors from JAKPharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top